Jefferies Financial Group Lowers Humana (NYSE:HUM) Price Target to $235.00

Humana (NYSE:HUM) had its price target cut by equities researchers at Jefferies Financial Group from $310.00 to $235.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the insurance provider’s stock. Jefferies Financial Group’s target price would suggest a potential upside of 27.77% from the stock’s previous close.

A number of other research analysts also recently commented on the stock. Truist Financial dropped their target price on shares of Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a research report on Monday, November 10th. Leerink Partners dropped their price objective on Humana from $267.00 to $185.00 and set a “market perform” rating on the stock in a report on Thursday. Wells Fargo & Company downgraded Humana from an “overweight” rating to a “cautious” rating in a report on Wednesday, January 7th. UBS Group decreased their target price on Humana from $285.00 to $195.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, Zacks Research lowered Humana from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 1st. Seven research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus price target of $239.46.

Humana Trading Up 2.8%

Shares of NYSE:HUM opened at $183.92 on Thursday. Humana has a 52 week low of $169.61 and a 52 week high of $315.35. The company’s 50 day moving average is $244.65 and its two-hundred day moving average is $260.85. The company has a market cap of $22.12 billion, a PE ratio of 18.73, a P/E/G ratio of 1.99 and a beta of 0.44. The company has a current ratio of 2.00, a quick ratio of 2.02 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The firm had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The company’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HUM. Montag A & Associates Inc. boosted its stake in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Fideuram Asset Management Ireland dac purchased a new position in Humana in the 4th quarter valued at approximately $27,000. CoreCap Advisors LLC raised its holdings in Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Rosenberg Matthew Hamilton boosted its position in Humana by 136.0% during the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Humana in the second quarter valued at $32,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.